leisure time -WSS

leisure time

author：knowledge 2025-08-31 16:42:26 - browse：42173

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： NIH confirmation hearing shows politicization of research

WSS

CDC director unscathed in first congressional testimony

BIO selects John Crowley as new CEO

Eli Lilly expects to double planned employment in Boston center

BIO selects John Crowley as new CEO

With clinical trial data readouts, here's how to spot spin

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

entertainment

Virginia high school admissions case could be legal follow

Despite FDA concern, risk that CAR

Anesthesiologist group: stop taking Ozempic before surgery

Takeda, Janssen join wearable maker to measure scratching

Trump demands the U.S. pay no more for drugs than other countries … again

Beam Therapeutics to lay off 20% of its staff, re

Supreme Court strikes down use of affirmative action

As biotech industry slumps, bioscience job market is upside down

Walensky prepares to leave CDC — and Congress — behind

CEOs share strategies for surviving biotech slump

entertainment

STAT Summit: How a Chicago ER doctor tackles gun violence

UnitedHealth’s board chair also owns a personal investment firm

30 years of 'Listening to Prozac'

UnitedHealth’s Optum accused of antitrust violations in California

Eli Lilly expects to double planned employment in Boston center

30 years of 'Listening to Prozac'

leisure time

knowledge

Wikipedia

focus